Fortrea Stock (NASDAQ:FTRE)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$18.86

52W Range

$16.53 - $41.02

50D Avg

$19.63

200D Avg

$27.55

Market Cap

$1.68B

Avg Vol (3M)

$1.52M

Beta

-

Div Yield

-

FTRE Company Profile


Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

15,500

IPO Date

Jun 20, 2023

Website

FTRE Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 24Mar 24
Europe$191.80M$208.30M
North America$319.70M$305.90M
Other Geographical Areas$163.40M$147.90M

Fiscal year ends in Dec 23 | Currency in USD

FTRE Financial Summary


Dec 23Dec 22Dec 21
Revenue$3.11B$3.10B$3.06B
Operating Income$63.10M$185.20M$114.30M
Net Income$-3.40M$58.40M$98.00M
EBITDA$190.70M$328.80M$301.80M
Basic EPS-$0.64$1.11
Diluted EPS-$0.64$1.11

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 08, 24 | 11:21 AM
Q2 24Aug 12, 24 | 1:13 PM
Q1 24May 13, 24 | 12:00 AM